Business

Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event

-- Phase 3 trial evaluating setmelanotide in pediatric patients ages

articleRhythm Pharmaceuticals, Inc.December 6, 20233/company/rhythm-pharmaceuticals-inc/news/rhythm-pharmaceuticals-announces-updates-on-mc4r-pathway-programs-at-rd-event-2023-12

Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event

About this update from Rhythm Pharmaceuticals, Inc.

[{"type":"text","content":"-- Phase 3 trial evaluating setmelanotide in pediatric patients ages 2-","length":93,"tagName":"div"}]

More updates from Rhythm Pharmaceuticals, Inc.